CRON:NSD-Cronos Group Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2.48

Change

+0.01 (+0.40)%

Market Cap

USD 1.00B

Volume

2.52M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

+0.88 (+0.63%)

USD 13.68B
VTRS Viatris Inc

+0.18 (+1.55%)

USD 13.36B
ITCI Intracellular Th

-1.54 (-2.19%)

USD 7.72B
LNTH Lantheus Holdings Inc

-2.65 (-3.39%)

USD 4.49B
ALKS Alkermes Plc

+0.19 (+0.80%)

USD 4.07B
ALVO Alvotech

-0.11 (-0.76%)

USD 4.06B
AVDL Avadel Pharmaceuticals PLC

+0.52 (+2.84%)

USD 3.44B
HCM HUTCHMED DRC

-0.41 (-2.10%)

USD 3.23B
INDV Indivior PLC Ordinary Shares

+0.02 (+0.11%)

USD 2.93B
EVO Evotec SE ADR

-0.10 (-1.86%)

USD 2.51B

ETFs Containing CRON

MJ Amplify Alternative Harve.. 6.21 % 0.75 %

+0.01 (+0%)

USD 0.25B
BUDX 3.84 % 0.00 %

N/A

N/A
PSY 0.00 % 0.76 %

N/A

N/A
SEED:CA 0.00 % 1.13 %

N/A

N/A
YOLO AdvisorShares Pure Cannab.. 0.00 % 0.00 %

-0.02 (0%)

USD 0.05B
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.00 %

N/A

CAD 0.09B
CNBS Amplify Seymour Cannabis .. 0.00 % 0.00 %

-0.03 (0%)

USD 0.03B
THCX 0.00 % 0.00 %

N/A

N/A
HMMJ:CA Global X Marijuana Life S.. 0.00 % 0.86 %

+0.18 (+0%)

CAD 0.08B
POTX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.66% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.66% 77% C+ 83% B
Trailing 12 Months  
Capital Gain 43.35% 82% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.35% 82% B 85% B
Trailing 5 Years  
Capital Gain -85.55% 40% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.55% 40% F 13% F
Average Annual (5 Year Horizon)  
Capital Gain -23.92% 34% F 15% F
Dividend Return -23.92% 34% F 15% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.27% 66% D+ 47% F
Risk Adjusted Return -62.51% 35% F 17% F
Market Capitalization 1.00B 75% C 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector